UNSPSC 51102867: Nystatin/oxytetracycline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102867 Nystatin/oxytetracycline is a Commodity code that nominally describes antibiotic pharmaceutical compounds, but recent state and local solicitations tagged with this code show material scope divergence — the actual buying activity under the code encompasses medical and first aid supplies for emergency response, naloxone procurement for community health initiatives, generic multi-source pharmaceuticals and OTC products for government health systems, and direct-to-manufacturer prescription fulfillment programs. State and local issuing bodies soliciting under this code include county health departments, municipal fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple states and jurisdictions. The procurement mix reflects healthcare operational procurement rather than narrow antibiotic compounds alone.

Recent solicitations span Florida, Texas, and Minnesota. The City of Tampa Fire Department released an IFB for medical and first aid supplies with an estimated contract value of $700,000 and response deadline of March 13, 2026, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5% bid discount. Seminole County, Florida issued IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: date appears erroneous in source materials). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, solicited generic multi-source pharmaceuticals and OTC products through RFP S1070000015802 with proposals due March 26, 2026 and contract effectiveness July 1, 2026, requiring vendor certification in cGMP and DSCSA compliance and contracted relationships with authorized wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, functioning as exploratory market research preceding formal procurement.